Bio/Pharma News

May 21, 2014

Pfizer will submit a NDA with FDA for palbociclib, a treatment for locally advanced or metastatic breast cancer.

May 21, 2014

BMS and AbbVie receive FDA breakthrough therapy designation for elotuzumab, an investigational humanized monoclonal antibody for multiple myeloma.

May 20, 2014

Novartis settles its litigation with the US subsidiary of Sun Pharma regarding Gleevec.

May 20, 2014

FDA issues complete response letter for Novartis' RLX030 for acute heart failure.

May 19, 2014

AstraZeneca rejects Pfizer's final offer of $118 billion for a proposed merger of the two companies.

May 15, 2014

Santen will purchase Merck's ophthalmology products business in Japan and key markets in Europe and Asia Pacific.

May 15, 2014

AstraZeneca will collaborate with the Medical Research Council Laboratory of Molecular Biology to fund a range of pre-clinical research projects.

May 12, 2014

Shire expands rare disease portfolio with acquisition of Lumena Pharmaceuticals.

May 01, 2014

PTSM: Pharmaceutical Technology Sourcing and Management

Gallus BioPharmaceuticals enters a cell line optimization and manufacturing agreement with Omni Bio Pharmaceutical.

April 30, 2014

BMS acquisition of iPierian advances BMS' pursuit of therapeutics for genetically defined diseases.